» Articles » PMID: 23475219

Adaptive Immunity Does Not Strongly Suppress Spontaneous Tumors in a Sleeping Beauty Model of Cancer

Overview
Journal J Immunol
Date 2013 Mar 12
PMID 23475219
Citations 24
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor immunosurveillance hypothesis describes a process by which the immune system recognizes and suppresses the growth of transformed cancer cells. A variety of epidemiological and experimental evidence supports this hypothesis. Nevertheless, there are a number of conflicting reports regarding the degree of immune protection conferred, the immune cell types responsible for protection, and the potential contributions of immunosuppressive therapies to tumor induction. The purpose of this study was to determine whether the adaptive immune system actively suppresses tumorigenesis in a Sleeping Beauty (SB) mouse model of cancer. SB transposon mutagenesis was performed in either a wild-type or immunocompromised (Rag2-null) background. Tumor latency and multiplicity were remarkably similar in both immune cohorts, suggesting that the adaptive immune system is not efficiently suppressing tumor formation in our model. Exceptions included skin tumors, which displayed increased multiplicity in wild-type animals, and leukemias, which developed with shorter latency in immune-deficient mice. Overall tumor distribution was also altered such that tumors affecting the gastrointestinal tract were more frequent and hemangiosarcomas were less frequent in immune-deficient mice compared with wild-type mice. Finally, genetic profiling of transposon-induced mutations identified significant differences in mutation prevalence for a number of genes, including Uba1. Taken together, these results indicate that B and T cells function to shape the genetic profile of tumors in various tumor types, despite being ineffective at clearing SB-induced tumors. To our knowledge, this study represents the first forward genetic screen designed to examine tumor immunosurveillance mechanisms.

Citing Articles

Cancer immune evasion, immunoediting and intratumour heterogeneity.

Roerden M, Spranger S Nat Rev Immunol. 2025; .

PMID: 39748116 DOI: 10.1038/s41577-024-01111-8.


dysfunction in VEXAS and cancer.

Sakuma M, Haferlach T, Walter W Oncotarget. 2024; 15:644-658.

PMID: 39347709 PMC: 11441413. DOI: 10.18632/oncotarget.28646.


Understanding cancer drug resistance with functional genomic screens: Application to MAPK inhibition in cutaneous melanoma.

Zhu E, Schillo J, Murray S, Riordan J, Dupuy A iScience. 2023; 26(10):107805.

PMID: 37860756 PMC: 10582486. DOI: 10.1016/j.isci.2023.107805.


Multi-omics analysis identifies RFX7 targets involved in tumor suppression and neuronal processes.

Schwab K, Coronel L, Riege K, Sacramento E, Rahnis N, Hackes D Cell Death Discov. 2023; 9(1):80.

PMID: 36864036 PMC: 9981735. DOI: 10.1038/s41420-023-01378-1.


Immunoediting instructs tumor metabolic reprogramming to support immune evasion.

Tsai C, Chuang Y, Li X, Yu Y, Tzeng S, Teoh S Cell Metab. 2023; 35(1):118-133.e7.

PMID: 36599297 PMC: 10375941. DOI: 10.1016/j.cmet.2022.12.003.


References
1.
Waldhauer I, Steinle A . NK cells and cancer immunosurveillance. Oncogene. 2008; 27(45):5932-43. DOI: 10.1038/onc.2008.267. View

2.
Shankaran V, Ikeda H, Bruce A, White J, Swanson P, Old L . IFNgamma and lymphocytes prevent primary tumour development and shape tumour immunogenicity. Nature. 2001; 410(6832):1107-11. DOI: 10.1038/35074122. View

3.
Hodge J, Greiner J, Tsang K, Sabzevari H, Kudo-Saito C, Grosenbach D . Costimulatory molecules as adjuvants for immunotherapy. Front Biosci. 2005; 11:788-803. DOI: 10.2741/1837. View

4.
Lennerz V, Fatho M, Gentilini C, Frye R, Lifke A, Ferel D . The response of autologous T cells to a human melanoma is dominated by mutated neoantigens. Proc Natl Acad Sci U S A. 2005; 102(44):16013-8. PMC: 1266037. DOI: 10.1073/pnas.0500090102. View

5.
Collier L, Adams D, Hackett C, Bendzick L, Akagi K, Davies M . Whole-body sleeping beauty mutagenesis can cause penetrant leukemia/lymphoma and rare high-grade glioma without associated embryonic lethality. Cancer Res. 2009; 69(21):8429-37. PMC: 2771123. DOI: 10.1158/0008-5472.CAN-09-1760. View